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Objectives The aim of this study was to assess the efficacy of radiofrequency catheter ablation (RFCA) in the treatment of
hypertrophic obstructive cardiomyopathy in children.
Background Hypertrophic obstructive cardiomyopathy is an uncommon cause of left ventricular outflow tract obstruction in
children. In symptomatic patients, open heart surgical myectomy has hitherto been the only therapeutic option.
Methods In 32 children, at a median age of 11.1 (range 2.9 to 17.5) years and weight of 31 (15 to 68) kg, ablation of the
hypertrophied septum was performed using a cool-tip ablation catheter via a femoral arterial approach. The me-
dian number of lesions was 27 (10 to 63) and fluoroscopic time was 24 (12 to 60) min.
Results The majority of patients demonstrated an immediate decrease in the catheter pullback gradient (mean 78.5 
26.2 mm Hg pre-RFCA versus mean 36.1  16.5 mm Hg post-RFCA, p  0.01) and a further reduction in the
Doppler echocardiographic gradient (mean 96.9  27.0 mm Hg pre-RFCA versus 32.7  27.1 mm Hg post-
RFCA, p  0.01) at follow-up. One patient died due to a paradoxical increase in left ventricular outflow tract ob-
struction, and another had persistent atrioventricular block that required permanent pacing. Six patients re-
quired further procedures (surgery, pacing, or further RFCA) during a median follow-up of 48 (3 to 144) months.
Conclusions The preliminary results of RFCA for septal reduction in children with hypertrophic cardiomyopathy are promising
and merit further evaluation. (J Am Coll Cardiol 2011;58:2501–10) © 2011 by the American College of Cardi-
ology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.020Hypertrophic cardiomyopathy (HCM) in childhood is a
heterogeneous disease with variable progression (1,2). Left
ventricular outflow tract obstruction (LVOTO), which is
dynamic in nature, is partly caused by systolic anterior
motion of the mitral valvular apparatus (3–5). Symptoms
include tiredness, dyspnea with effort, chest pain, exercise-
related syncope, or sudden arrhythmic death (6–8). Treat-
ment is aimed at palliation. Whereas in adults myectomy
results in elimination of symptoms and improved long-term
survival, similar data in children are scarce (9–14). Percu-
taneous alcohol septal ablation (ASA) was developed as a
therapeutic alternative in adult patients for relief of
LVOTO (15–18). In children, however, this approach is
technically not feasible. With the establishment of radiofre-
quency catheter ablation (RFCA) for arrhythmias, increas-
ing the depth of the radiofrequency (RF) lesions has been
achieved with a variety of advances in catheter technologies,
including the use of cool-tip irrigated catheters (19–21).
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accepted September 6, 2011.We have previously demonstrated the ability of percutane-
ous RFCA to relieve symptomatic LVOTO and also to
reduce or dissolve myocardial tumors (22–24). We report on
the extended application of this technique in a series of
children treated by 2 tertiary referral centers.
Methods
Patients. Between June 1999 and January 2011, 33 patients
(20 males), age between 2.9 and 17.5 years (median 11.1
years), and weighing between 15 and 68 kg (median 31 kg),
were considered for percutaneous RFCA. Patients were
chosen for the RFCA procedure after having failed phar-
macological therapy, and surgical myectomy was considered
as indicated. RFCA was offered as an alternative to surgical
myectomy in both institutions; apart from 2 children whose
parents opted for surgery, the remaining patients underwent
RFCA as the primary treatment during the study period.
Presenting symptoms were increasing tiredness as reported
by the parents or the patient (n  28), dyspnea on exertion
and exercise intolerance (n  16), anginal chest pain with
exertion (n 3), and recurrent nonarrhythmic syncope (n
8). One child had previously undergone surgical septal
myectomy. Standard outpatient investigations included a
12-lead electrocardiogram and Holter, transthoracic Dopp-
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the degree of myocardial septal
hypertrophy and the resting gradi-
ent across the left ventricular out-
flow tract (LVOT). Informed con-
sent was obtained from the parents
for every interventional procedure.
Institutional review board approval
was also obtained from the hospi-
tal ethics committees at both in-
stitutions for the use of RFCA
procedure as nonstandard medi-
cal care.
Procedure. Procedures were
performed under general anesthesia.
Radiolucent defibrillator pads
were routinely placed for remote
defibrillation. Following place-
ment of the femoral venous and
arterial sheaths, all patients were
routinely heparinized (100 U/kg bolus dose, up to a maxi-
mum dose of 5,000 U), and dosage was adjusted to maintain
activated clotting time between 250 and 300 s.
TRANSESOPHAGEAL ECHOCARDIOGRAPHY. A detailed as-
essment of the LVOT was performed by transesophageal
chocardiography (TEE), which also helped to direct ma-
ipulation of the ablation catheter to the desired anatomic
ite. The desired anatomic site was the most prominent
eptal bulge producing narrowing of the LVOT; this was
lso the most frequent (but not invariably) point of contact
f the mitral valve apparatus to the septum in systole.
PACING. Via the femoral vein, temporary pacing electrodes
were placed in the right atrium and ventricle. In the initial
12 procedures, baseline pacing was carried out using differ-
ent atrioventricular (AV) delays (with 10 ms decrements
Abbreviations
and Acronyms
ASA  alcohol septal
ablation
AV  atrioventricular
HCM  hypertrophic
cardiomyopathy
LDH  lactate
dehydrogenase
LVOT  left ventricular
outflow tract
LVOTO  left ventricular
outflow tract obstruction
RF  radiofrequency
RFCA  radiofrequency
catheter ablation
TEE  transesophageal
echocardiography
Figure 1 Angiogram in RAO Projection and Corresponding Loca
(A) Angiogram in the right anterior oblique (RAO) projection. There is marked redu
(B) LocaLisa image corresponding to the angiogram. The blue dots represent site
radiofrequency lesions. The green dots represent sites where a bundle branch potfrom baseline), while simultaneously measuring the pullback
gradient across the LVOT using a 4-F Multitrack catheter
(NuMed, Best, the Netherlands). If there was a substantial
decrease (50% from the baseline gradient) in the measured
gradient, this was interpreted to mean that the patient
might eventually benefit from permanent dual-chamber
pacing. This information was obtained with a view to
considering permanent pacing as a future option, in the
event of nonimprovement of gradient following the RFCA
procedure.
ANGIOGRAPHY. Biplane left ventricular angiography was
performed, in the 30° right anterior oblique and 60° left
anterior oblique projections, to show the level and extent of
obstruction (Fig. 1A). In patients presenting with angina,
selective left coronary angiograms were obtained to exclude
myocardial bridging.
MAPPING THE CONDUCTION SYSTEM. The proximal His
bundle was routinely mapped, and its anatomic relation to
the LVOTO noted. The LocaLisa mapping system
(Medtronic, Minneapolis, Minnesota) was routinely used
for this purpose at 1 of the centers. In previous studies, we
and others have demonstrated that this system is extremely
accurate for continuous localization of standard intracardiac
electrodes and, in particular, the His bundle over prolonged
periods (25–28). Individual RF lesions were also marked on
the LocaLisa image (Fig. 1B). The CARTO (Biosense
Webster, Diamond Bar, California) electroanatomic map-
ping system was used in 2 patients to obtain similar
information.
ABLATION. Via a 7-F introducer placed in the femoral
artery, a 4-mm cool-tip ablation catheter (Sprinklr,
Medtronic; or Thermocool, Biosense Webster, Johnson &
Johnson Medical, Waterloo, Belgium) or a catheter with an
8-mm ablation electrode (n  2; Celsius, Biosense Web-
Image
left ventricular cavity volume, and the subaortic obstruction is clearly seen.
e His bundle electrograms were recorded. The red dots represent individual
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manipulation and mapping, a normal saline infusion was
run through the catheter at 0.5 to 3 ml/min, increasing to 10
to 20 ml/min during application of each radiofrequency
lesion. Smaller patients received lower flow rates to avoid
fluid overload, and they also received a single dose of
intravenous furosemide (2 mg/kg) during the procedure.
Radiofrequency ablation was commenced at the most
apical part of the obstruction. Individual lesions were timed
for between 60 and 120 s, with a power setting of 60 W.
Catheter tip temperature and impedance were continuously
monitored. Linear applications of RF lesions were carried
out from this location, working toward the aortic valve. The
distance of each lesion from the His bundle was continu-
ously monitored in patients in whom LocaLisa or CARTO
was used. Local electrograms recorded from the ablation
catheter were checked for His bundle potentials, and if His
bundle potentials were present, no energy was delivered at
these sites. If such a site was considered a potential target for
RF ablation for anatomical reasons, an attempt was made to
distinguish a fascicular potential from a proximal His
bundle electrogram, by pacing at this site and measuring the
Figure 2 Different RF Catheter Approaches to the Hypertrophie
In A and B, the hypertrophied septum is directly approached, with the ablation cat
anterior oblique [LAO] projections, respectively). In C and D (RAO and LAO projecti
the target tissue. RF  radiofrequency.paced QRS duration. The RF lesions were applied along
different planes of the ventricular septum (to achieve at least
3 lines of lesions between the most apical part of the
obstruction and the region under the aortic valve (Fig. 1).
Occasionally, and usually in older patients, additional ma-
neuvers were required: for example, curving the catheter on
itself within the left ventricular cavity, and then gradually
releasing the curve when approaching the target area, to
allow the ablation electrode to contact the septal myocar-
dium, (Figs. 2A to 2D). In selected patients, a long sheath
was used to maintain stable catheter position during RFCA.
The number of lesions was determined purely on anatomical
considerations, to cover the target area adequately (the
septal bulge producing anatomic obstruction in the LVOT).
ECHOCARDIOGRAPHY. TEE during the procedure and
transthoracic echocardiography at the end of the procedure
were used to measure the acute change in Doppler gradient,
assess aortic and mitral valve function, and to exclude a
pericardial effusion.
CARDIAC ENZYMES. In the majority of patients, serum
samples for measurement of cardiac troponin T were ob-
ptum
being stabilized by the use of a long sheath (right anterior oblique [RAO] and left
he ablation catheter is curved within the left ventricle to facilitate contact withd Se
heter
ons), t
Demographic Data, Procedural Details and Outcomes for Children Undergoing RFCA for Septal HypertrophyTable 1 Demographic Data, Procedural Details and Outcomes for Children Undergoing RFCA for Septal Hypertrophy
Patient # Age, Sex
Weight
(kg) Lesions
Fluoroscopic Time
(min)
Troponin T
(Maximum) g/L
Pullback
Gradient
mm Hg (Pre-)
Pullback
Gradient
mm Hg (Post-)
Doppler
Gradient
mm Hg (Pre-)
Lowest Doppler
Gradient
mm Hg (Post) Complications Comments
1 5.0, M 17 17 26 8.0 50 35 80 25 VF requiring cardioversion
70 50 80 — Myectomy and mitral valve
replacement
2 11.1, F 38 50 28 5.0 60 14 90 16 None ICD 5 yrs post-ablation
3 15.4, F 39 18 23 6.4 52 22 64 25 None
4 12.2, F 26 31 22 9.2 90 38 96 20 None
5 12.3, M 31 16 24 8.1 80 48 105 56 None
15.5 48 35 22 14.9 62 35 90 18 None
6 11.7, F 42 28 19 9.1 90 37 106 20 None
7 6.5, M 23 28 25 11.7 112 41 120 20 None
8 8.3, M 25 28 31 12.9 120 25 126 0 AV block Pacemaker
9 4.6, F 15 31 17 15.2 130 — 155 — Acute LV dysfunction,
ECMO
Died
10 12.5, F 37 22 24 14.6 80 35 104 16 None
11 2.9, F 18 60 35 25.0 70 10 80 16 Sinus bradycardia In ICU for 48 h
12 14.7, F 43 21 22 9.8 82 38 96 18 None
13 12.0, M 41 28 21.5 11.2 74 32 90 16 None
14 11.1, M 39 24 33 8.8 86 30 104 40 None
15 9.0, M 26 22 29 14.4 102 44 120 36 None
16 14.1, M 63 32 18 15.1 90 39 104 20 None
17 13.8, M 51 22 26 12.3 108 35 120 40 None
18 8.5, M 30 17 22 12.5 78 33 100 32 None
19 12.7, M 47 60 14.5 31.0 85 30 120 20 VF requiring cardioversion
20 2.9, F 15 47 10.5 28.3 65 20 90 15 None Previous surgical myectomy
21 17.5, F 26 18 24 —
CK (MB) 90
LDH 1041
64 30 30 30 Groin hematoma Noonan syndrome
22 16.0, F 40 12 21 8.6
CK (MB) 595
92 21 74 74 None Nonsustained VT at follow-up
treated with beta-blocker.
Died in sleep 2.5 yrs after
RFA
23 5.0, M 30 12 46 —
CK (MB) 397
LDH 1749
112 49 122 52 AV block (transient) 8-mm cool-tip catheter used.
Permanent pacemaker;
recovery of AV conduction
1 week later
8.1 53 Troponin T 0.78
CK (MB) 251
50 50 64 64 Re-do RFA, but not at ideal
target sites, due to
proximity to His bundle
15.4 64 64 Pacemaker generator
replacement, no RFA
procedure attempted
Continued on next page
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ContinuedTable 1 Continued
Patient # Age, Sex
Weight
(kg) Lesions
Fluoroscopic Time
(min)
Troponin T
(Maximum) g/L
Pullback
Gradient
mm Hg (Pre-)
Pullback
Gradient
mm Hg (Post-)
Doppler
Gradient
mm Hg (Pre-)
Lowest Doppler
Gradient
mm Hg (Post) Complications Comments
24 5.0, F 19 10 24 CK-MB 251 64 64 100 43 None 8-mm cool-tip catheter used
6.0 21 22 18 — 20 20 100 112
54 (paced)
None Elective permanent
pacing, based on pacing-
related gradient reduction
12.5 39 21 30 2.8 30 30 100 30 Superficial burn from
earthing plate
8-mm cool-tip catheter used
14.0 12 Elective generator
replacement; no RFA
25 12.1, M 42 29 14 20.1 110 33 122 25 None
26 4.0, M 15 19 — 90 90 140 140 None Surgical myectomy
27 16.0, M 68 24 15 1.19 10 10 35 0 None
28 5.0, M 16 21 35 4.6 71 55 70 15 None Reduction in severity of MR
after ablation
29 15.0, F 48 24 22.5 1.3 45 — 88 16 None
30 13.0, M 46 20 31 1.62 32 32 144 62 None Frequent ventricular
premature beats, on
beta-blocker therapy
31 9.0, M 32 20 34 —
CK (MB) 1,772
LDH 1,979
56 33 64 25 None
32 7.5, M 29 24 17 3.1 61 61 92 64 None
33 10.0, M LVOTO from mitral valve
tissue; no RFA performed
AV atrioventricular; CK creatine kinase; CK-MB creatine kinase-myocardial band; ECMO extracorporeal membrane oxygenator; ICD implantable cardioverter-defibrillator; ICU intensive care unit; LDH low-dose heparin; LV left ventricle; LVOTO left ventricular
outflow tract obstruction; MB  myocardial band; MR  mitral regurgitation; RFA  radiofrequency ablation; RFCA  radiofrequency catheter ablation; VF  ventricular fibrillation; VT  ventricular tachycardia.
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Catheter Ablation of Septal Hypertrophy December 6, 2011:2501–10tained at baseline, immediately following the ablation pro-
cedure, and at 6-h intervals thereafter for up to 24 h after
the procedure, to allow for a semiquantitative estimation of
myocardial necrosis. In some patients, creatine kinase-
myocardial band or lactate dehydrogenase (LDH) values
were also obtained.
Statistical analysis. Statistical analysis was performed us-
ing IBM-SPSS (version 19.0, SPSS Inc., Chicago, Illinois).
Gradients before and after were not normally distributed
and are presented as median and range. Additionally, we
also calculated mean values for pre- and post-pullback and
Doppler gradients. To compare the gradients before and
after intervention, we used the Wilcoxon matched-pairs
signed-rank test. p values 0.01 were considered to be
significant. Freedom from reintervention during follow-up
was drawn with the Kaplan-Meier method.
Results
Patients. Thirty-two of the 33 patients underwent RF
ablation. One child with Friedreich ataxia had aberrant
mitral valve papillary muscle attachments to the ventricular
septum on pre-procedural TEE, and no RFCA was
performed.
ABLATION. The number of RF lesions ranged between 10
nd 63 (median 27), and fluoroscopy time between 12 and
0 min (median 24 min). Routine use of a mapping system
educed fluoroscopy time and ensured the application of
losely spaced lesions. TEE was useful in monitoring
atheter position, and the effect of the lesion, with the
blated area being characterized by irrigation fluid bubble
ormation followed by increased echodensity.
COMPLICATIONS. There was 1 procedure-related death in a
4-year-old girl, with a pre-procedure pullback gradient of
130 mm Hg. At the end of the procedure, prior to removal
of all the vascular sheaths, the patient developed acute left
ventricular dysfunction (left ventricular end-diastolic pres-
sure of 34 mm Hg). TEE demonstrated a paradoxical
increase in the degree of LVOTO due to tissue edema at the
ablation sites. Following cardiopulmonary resuscitation, she
was put on an extracorporeal membrane oxygenator for 3
days, during which there was no improvement in left
ventricular function, and treatment was discontinued. Au-
topsy was not performed. Two patients had complete AV
block and required implantation of a dual-chamber pace-
maker. In one of them, AV block resolved within 1 week of
the procedure. Two patients developed ventricular fibrilla-
tion related to catheter manipulation in the left ventricle and
required direct current cardioversion. Minor complications
included a groin hematoma (n  1) and superficial burn at
the site of the earthing electrode (n  1, with no residual
carring).
RELIEF OF OBSTRUCTION. Gradient reduction, as measured
by pullback directly after the procedure, was recorded in the
majority of survivors, although individual responses werevariable (Table 1). The median pre-procedure pullback
gradient was 80 mm Hg (range 10 to 130 mm Hg, mean
78.5  26.2) and decreased to 34 mm Hg (range 10 to 90
mm Hg, mean: 36.1  16.5, p  0.01). Follow-up
echocardiography, performed prior to discharge from hos-
pital, at 6 weeks, at 3 and 6 months post-procedure, and
annually thereafter, showed that there was a continuous
decrease in the gradient during this interval. The Doppler
echocardiographic gradient pre-procedure ranged between
30 and 144 mm Hg (median 100 mm Hg, mean 96.9 
27.0 mm Hg). The post-procedure Doppler gradient at the
last follow-up ranged between 0 and 140 mm Hg (median
25 mm Hg, mean 32.7  27.1 mm Hg, p  0.01) (Fig. 3).
Apart from the patients requiring reinterventions (surgical
or redo-RFCA), who were identified within this interval,
the gradient reduction has been maintained at the most
recent follow-up in the remaining patients, some of whom
have had further minor gradient reductions.
CARDIAC ENZYMES. Troponin T values rose from 0.1
g/l pre-procedure to a median peak value of 11.2 g/l
(range 1.19 to 31.0 g/l). Creatine kinase-myocardial band
baseline laboratory reference range 60 to 365 IU/l) and
DH (baseline laboratory reference range 900 IU/l)
alues, where measured, also showed a significant increase
Table 1).
POST-PROCEDURAL FOLLOW-UP. All patients, except the
girl who died, were extubated directly after the catheteriza-
tion procedure. One child who had a persistent sinus
bradycardia was monitored on the intensive care unit for a
period of 48 h. Oral aspirin (5 mg/kg/day) was commenced
on the evening of the procedure and continued for 6
months. Patients were monitored for 24 to 48 h, and
subsequently discharged from the hospital. One child (pa-
tient 27) (Table 1) showed an acute reduction in the severity
of mitral valve regurgitation directly after the procedure. Of
the remaining patients, there was a decrease in the degree of
pre-existing mitral valve regurgitation in a further 11 pa-
tients, all of whom had had varying degrees of systolic
anterior movement of the mitral valve. In particular, apart
from the single patient who died, none of the others demonstrated
an increase in the degree of mitral regurgitation.
LATE FOLLOW-UP. All survivors have undergone serial out-
patient follow-up (median follow-up duration of 48
months; range 3 to 144 months). All but 1 of the patients
had symptomatic improvement following the procedure:
tiredness with exertion (28 pre- to 1 post-RFCA); dyspnea
with effort (16 to 0); exertional angina (3 to 0); nonarrhyth-
mic syncope (8 to 0). Formal exercise testing was not
performed in this series for several reasons: young patient
age, absence of pre-procedure exercise tests, patient referral
from other countries without facilities for standardized
exercise testing.
Additional procedures were undertaken in 5 patients.
Patient #26 (Table 1, Fig. 4) in whom there was no change
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Four children (Patients #1, #5, #23, and #24) underwent a
second RFA procedure between 6 and 64 months after
initial ablation. All had demonstrated a good acute response
to the initial RFCA. TEE during RFCA demonstrated that
aberrant papillary muscle attachments of the mitral valve
contributed significantly to residual LVOTO in Patient #1,
who underwent surgical myectomy and mitral valve replace-
ment during the same hospital admission. In Patient #5
there was a further reduction in LVOTO following the
second ablation. Patient #23 had prominent His bundle
potentials recorded at the ideal ablation site during the
second procedure; despite having a permanent pacemaker, it
was decided not to produce iatrogenic AV block, and RF
lesions were applied at adjacent LVOT sites without His
potentials. Patient #24 had no improvement in LVOTO
during the second RFA. Temporary AV sequential pacing,
however, showed a marked improvement in LVOTO, and
a permanent pacemaker was therefore implanted. At 39
months after this procedure, she underwent a third RFCA
for recurrent LVOTO, with an excellent response. Figure 4
shows that there was an 87.5% freedom from reinterven-
tions at 10 years of follow-up.
LATE ARRHYTHMIAS. Patient #2 with familial HCM has
had implantable cardioverter-defibrillator implantation, 5
years after RFCA, for recurrent sustained monomorphic
ventricular tachycardia. Patient #22 died in her sleep, 2.5
years after RF ablation. She had been noted at follow-up to
Figure 3 Box Plot Showing the Catheter Pullback and Doppler
The median gradient, with interquartile range is shown. Outliers are shown as circhave recurrent nonsustained (asymptomatic) ventricular ar-rhythmia and had been treated with a beta-blocker. The
mechanism of death was presumed to be arrhythmic.
Discussion
Surgery. Timely relief of LVOTO in the setting of HCM
has been shown in adults to relieve symptoms, restore
normal exercise tolerance, and improve life expectancy. In
selected centers, surgical myectomy in children results in an
excellent hemodynamic outcome, with very low mortality.
In the series of Theodoro et al. (9) from the Mayo Clinic
(n  25, over a 20-year period), there were no operative or
late deaths (although 2 patients required circulatory support
with an aortic balloon pump), and 2 patients required a
repeat surgical myectomy. Individual surgical series for relief
of LVOTO in pediatric patients are small. The median age
of the patients in the Mayo Clinic series was 14 years (range
2 months to 20 years), which is considerably older than in
our series. Septal myectomy involves the resection of a
relatively small amount of muscle from the proximal ven-
tricular septum (approximately 3 to 5 g) (29). This appears
to widen the LVOT sufficiently and to abolish the Venturi
forces that produce systolic anterior motion of the mitral
valve leaflets (30–32). This has important implications for
the RFCA procedure described here, as the effective lesion
size and depth required to relieve LVOTO is sufficiently
circumscribed to be amenable to catheter ablation.
RFCA. The use of electrical energy to treat LVOTO was
cardiographic Gradients Pre- and Post-Ablation
mbers correspond to patient number in Table 1).Echo
les (nuinitially described by Armistead et al. (33) during open heart
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ablation allows the use of longer durations and higher
powers of radiofrequency current to achieve a larger lesion
volume and lesion depths of 6 to 10 mm (34–38). Based on
these studies and on clinical data, we aimed to achieve
catheter tip temperatures between 40°C and 50°C, with a
nominal power setting of 60 W. The mechanism of RF
effect is most likely tissue desiccation, followed by muscle
atrophy. Lawrenz et al. (39) recently demonstrated the
beneficial effect of RF ablation in adult patients with
LVOTO. They suggested that the mechanism of benefit
might be the result of a local movement disorder, preventing
the treated segment of septum from contracting effectively.
This effect was also seen in some of our patients (Fig. 5).
In50% of their patients, they performed RF ablation from
the right ventricle (39). Given that the septal thickness in
some patients may exceed 30 mm, it is unclear how
transcatheter lesions on the right ventricular septum might
create adequate relief of LVOTO. If validated from further
Figure 4 Kaplan-Meier Curve Demonstrating Freedom From Rei
Relation to Duration of Follow-Up in this Series
The number of patients available for each follow-up interval is shown on the top. L
Figure 5 Transthoracic Echocardiograms at 3 Years of Follow-U
(A) The ablation site (seen as the echodense area of the septum) does not contraobservations, however, this approach might be particularly
suited to young children.
Permanent pacing. Sequential AV pacing, which was per-
formed in some children early in our experience, was
discontinued after data from adult studies demonstrated no
consistent benefit (40–42). No attempt was made during
RFCA to deliberately create left bundle branch block, and
none of the patients had left bundle branch block at
follow-up (43).
Assessment of outcome. Serial echocardiographic follow-up
showed further improvement in LVOTO, suggesting that
there is continuing tissue remodeling following the procedure.
Peak serum cardiac enzyme levels did not appear to correlate
with the degree of gradient reduction and might not have any
long-term prognostic value.
Are the RF lesions potentially arrhythmogenic? ASA is
associated with intramyocardial scarring, and the same applies
to RFCA. At follow-up, ASA patients appear to be at a higher
risk for arrhythmic events when compared with surgical my-
ention for Recurrent LVOTO in
 left ventricular outflow tract observation.
st-Ablation
h the rest of the septum. (B) Color flow mapping confirms laminar flow.nterv
VOTOp Po
ct wit
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infant lamb model that RF lesions increase in size, with loss
of demarcation of the borders and fibrous tissue invasion of
the surrounding normal myocardium. Two patients in our
series developed a late arrhythmia (1 nonsustained) and may
have had natural progression of their HCM. These data are
comparable to the best pediatric surgical series (9).
How to avoid procedural complications? Carrying out
RF ablation at a very advanced stage of disease may be
associated with a higher risk of paradoxical increase in
LVOTO from tissue edema, and this needs to be considered
in planning therapy and the timing of RFCA. The safety of
the procedure might be improved by careful anticoagulation,
use of smaller fluid volumes to irrigate the catheter tip, and
the judicious use of diuretics to avoid fluid overload. Two
patients developed AV block (1 recovered) and required
permanent pacing.
Retrospective evaluation of the local electrograms at the
ablation site did not identify a clear His potential. In
addition, 2 patients had transient ventricular fibrillation,
which is a risk associated with prolonged catheter manipu-
lation in the left ventricle. These risks are indeed higher,
when compared with surgery. It must be stressed, however,
that surgical series are small, and not all surgical series have
shown results compared with the Mayo Clinic gold standard
(where 1 patient required permanent pacing, and 2 patients
required temporary use of an aortic balloon pump) (9).
Aberrant mitral valve papillary muscle attachments might
play an important role in causing LVOTO and should be
identified by pre-procedural TEE.
Conclusions
RFCA adds to the therapeutic options available for relief of
symptomatic LVOTO in young patients. The benefits
include ease of application, use of standard catheter and
ablation equipment, repeatability, and short hospital stay.
The procedure is more controlled than ASA. Identification
of the His bundle and preservation of AV conduction are
also potential benefits. If the safety and efficacy of RFCA
can be established in larger series, it may result in a lowering
of the threshold for interventional therapy of HCM in
children.
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